INOVIO Pharmaceuticals, Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Inovio is a clinical-stage developer of DNA vaccines and electroporation delivery technology. It had no approved human products and no product-sales revenue; revenue came mainly from grants, government contracts, licenses and collaborations.
Financial performance
| Metric | Q2 2012 | Six months 2012 | Comparable 2011 |
|---|---|---|---|
| Revenue | $436,000 | $2.13 million | $2.42 million Q2; $5.53 million six months |
| Research and development | $4.53 million | $8.57 million | $4.46 million Q2; $8.89 million six months |
| General and administrative | $2.70 million | $5.18 million | $3.09 million Q2; $6.41 million six months |
| Loss from operations | $6.79 million | $10.97 million | $5.14 million Q2; $9.52 million six months |
| Net loss attributable to Inovio | $4.13 million | $12.39 million | $2.82 million Q2; $5.23 million six months |
| Loss per share | $0.03 | $0.09 | $0.02 Q2; $0.04 six months |
| Operating cash used | $10.75 million | $9.96 million for six months |
Gross margin is not reported; the filing presents operating expenses rather than product cost of sales. Revenue fell primarily because of lower NIAID contract revenue and no PATH grant revenue in 2012. Six-month operating expenses declined, particularly G&A, but operating loss widened as revenue fell. Q2 net loss includes a $3.59 million noncash gain from revaluing common-stock warrant liabilities; the six-month warrant fair-value gain was only $47,000, while the loss on the affiliated investment was $1.55 million.
Liquidity, balance sheet and capital
- At June 30, cash and cash equivalents were $5.95 million and short-term investments were $13.49 million, totaling $19.44 million. Working capital was $11.1 million, down from $20.9 million at year-end 2011.
- Total assets were $48.60 million; total liabilities were $12.24 million. The filing reports no conventional borrowings; the $5.04 million current common-stock warrant liability is a fair-value accounting liability.
- Cash and cash equivalents declined by $11.40 million in the first half. Investing cash use was $0.65 million; there was no financing cash flow in the period.
- In June, Inovio established an at-the-market equity program for up to $25 million gross, with a 3% placement fee. No shares had been sold under it by June 30.
- Common shares outstanding were 134,968,394 at June 30 and August 2. Options, warrants and convertible preferred stock represented 38.2 million potential common shares excluded from diluted loss per share as anti-dilutive.
Outlook, commentary and risks
- Management said existing cash and short-term investments were expected to fund planned working-capital needs into the third quarter of 2013. It expected to rely on external financing thereafter and stated it may never achieve positive cash flow.
- The company had a $222.5 million accumulated deficit and expected substantial continuing losses to fund R&D, preclinical work, clinical trials and regulatory activity. Management provided no revenue or earnings guidance.
- Clinical programs included HPV/cervical cancer, avian influenza, prostate cancer, leukemia, HCV and HIV; universal influenza and other candidates remained in preclinical research. The filing highlights clinical, regulatory, manufacturing, funding, competition, collaboration and intellectual-property risks.
- VGX International was to fund IND-enabling and initial Phase I/II studies for hepatitis B and C candidates in exchange for specified Asian rights. Separately, $2.5 million of scheduled OncoSec payments was not recorded as a receivable because collection was not reasonably assured; payment timing had been extended in exchange for warrants.
- Management reported effective disclosure controls at June 30 and no material change in internal control over financial reporting during the quarter. The filing reported no applicable legal proceedings.
Important facts for investors to verify
- Whether the stated runway into Q3 2013 remains supportable given the $10.75 million first-half operating cash use and lower working capital.
- Progress and funding under the NIAID contract, other grants and collaborations, including whether revenue concentration or contract timing has changed.
- Clinical-trial progress, results, timelines and manufacturing readiness for the named programs.
- Potential dilution and proceeds from the $25 million at-the-market program, plus the terms and potential dilution of outstanding warrants and options.
- Collection prospects and revised payment schedule for the unrecorded $2.5 million due from OncoSec, and valuation assumptions for warrant assets and liabilities.